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Fecal occult blood test is useful first step

M. D. Anderson researchers stress
importance of annual
colorectal cancer screening
Cancer Detection

Bernard Levin is vice
president for cancer
prevention

Constance Johnson is a
senior research nurse in
the Office of the Vice
President for Cancer
Prevention

While many people have regular mammograms and prostate cancer tests, few are screened
for colorectal cancer, despite its frequency.
"Colorectal cancer is very common;'' said Bernard Levin, M.D., vice president for cancer
prevention at M. D. Anderson Cancer Center.
"In the United States, there is an overall lifetime risk of about 6%, or 1 in 16. There are
138,000 new cases every year, and about 56,000
deaths." That makes colorectal cancer the second most common cause of death from cancer
in the United States. And although the overall
5-year survival rate for patients with colorectal
cancer is not as good as one would like ( about
5 2 %) , the survival rate for those with earlystage disease is close to 100%. It is therefore
imperative to identify people with colorectal
cancer as early as possible.
Levin and other physicians and researchers at
M. D. Anderson Cancer Center therefore strongly
recommend annual colorectal cancer screening
for the general population beginning at age 50.
The screening tests commonly used to detect
colorectal cancer in asymptomatic individuals are
the digital rectal examination, the fecal occult
blood test (FOBT), and flexible sigmoidoscopy.
The double-contrast barium enema and
colonoscopy may also be used.
Fecal occult blood test is recommended
The FOBT, although not a specific test for
cancer, tests for hidden blood in the stool, a sign
of colorectal cancer. Reports on the test's sensitivity and specificity have been variable, but researchers at the University of Minnesota reported
a test sensitivity of 80% when the test was repeated annually over 13 years. The FOBT is most

effective when used annually for many years, said
Levin, rather than as a one-time test.
The FOBT is an easy way for primary care
physicians to screen for early colon cancer. And
it's inexpensive: it costs only about $10.
"The actual test itself is not that sophisticated," said Levin. Nearly all FOBTs test for the
presence of blood or blood by-products in stool
samples. There are two main types of tests. The
immunochemical tests specifically detect human
hemoglobin in the stool. "Immunochemical tests
will most likely replace the guaiac-based tests,"
predicted Levin. The guaiac-based tests, which
are simpler and more commonly used, involve
guaiac-impregnated paper that when treated with
hydrogen peroxidase turns blue in the presence
of peroxidase-like activity in the stool. Unfortunately, because the test is not specific for hemoglobin, some vegetables with peroxidase-like
activity and some foods that contain heme (such
as meat) cause false positives in guaiac-based
FOBTs. Patients must avoid eating those things
before taking the tests.
False positives can also occur because some
medical conditions other than colorectal cancer
and some medications cause low but detectable
levels of blood loss. One example is the gastrointestinal bleeding associated with regular aspirin use; thus, aspirin also must be avoided before
stool sample collection for the FOBT.

Study reveals patient reluctance
The guaiac-based tests have been used for
more than 20 years, with some modifications. In
a recent report submitted for publication, Levin,
Kenneth Hess, Ph.D., of the M. D. Anderson
Department of Biomathematics, and Constance
continued on page 2
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Levin and his colleagues are about to begin a
national program to inform the public of the
importance of testing for colorectal cancer.

M. Johnson, B.S.N., of the Division of Cancer
Prevention compared three FOBTs: the
nonhydrated Hemoccult® FOBTand two modified versions, the rehydrated Hemoccult® and
the Hemoccult® Sensa®. In the rehydrated test,
a drop of water is added to rehydrate the stool
sample. This step has been shown to increase the
number of positive tests, but mostly by increasing
the number of false positives. The Hemoccult®
Sensa® is more sensitive than the standard
Hemoccult® because it contains a color enhancer
that intensifies the color of a positive test.
In the M. D. Anderson study, kits for each of
the three tests were given to over 85,000 people
by a Houston pharmacy chain and various minority community groups. Radio and television public service announcements and videos at the test
distribution sites explained the FOBT procedure
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The testing kit used in M . D. Anderson's comparative study of three types of FOBTs.
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and its importance. Every day for three days, each
subject placed a pea-sized stool sample on a special card for each of the tests. ( Collecting samples
for three days increases the probability of detecting intermittent bleeding.) "It was complicated,
but not as hard as using a VCR," joked Levin.
The study showed that th e re hydrated
Hemoccult® test had the highest positivity rate
but the lowest positive predictive value. (The
positivity rate is the percentage of all test results
that are positive, whereas the positive predictive
value is the percentage of positive test results in
patients shown by colonoscopy to have colorectal
cancer.) The nonhydrated Hemoccult® test had
the lowest positivity rate and the highest positive
predictive value . The Hemoccult® Sensa® had a
positive predictive value nearly as high as that of
the nonhydrated Hemoccult®.
However, only about 13% of the
study:s subjects completed the tests.
One reason for the low response, said
Levin, is that using nine test slides may
have made the test too complicated.
"People are also scared about getting
a positive test, so they don't want to
be involved in any kind of colorectal
cancer screening," he said. To address
this problem, Levin and his colleagues
at M. D. Anderson and around the
country are about to begin a national
program through the Digestive Health
Initiative to inform the public of the
importance of testing for colorectal
cancer. Their efforts would be easier if
there were a celebrity spokesperson for
colorectal cancer awareness, as there is
for breast cancer and prostate cancer.
Immediately after President Reagan
had his colon polyp s removed,
colorectal cancer screening increased
temporarily.
Even when people are more aware
of the importance of colorectal cancer
testing, they may still be reluctant to
do the FOBT because they must collect stool samples. Using one type of
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"It's the adequacy of follow-up and
the management of the condition
afterward that are most important."

over-the-counter test is appealing because there
is no direct contact with stool. (The test is performed by dipping a test strip in the toilet basin
containing the stool.) While Levin is in favor of
making colorectal cancer tests as widely available
as possible, he doesn't recommend the over-thecounter FOBT because it is less accurate than the
physician-administered tests and not well standardized and because there may be no one to
help the patients interpret and follow up on the
home tests. "I'm a great believer in people having
the right to control their own destinies," he said.
"But I advise that they get tested for colorectal
cancer through a physician or nurse, someone
trained to judge their overall risk for developing
the cancer. It's the adequacy of follow-up and the
management of the condition afterward that are
most important."
Positive FOBT warrants further testing
Surprisingly, many patients who get FOBTs
through physicians aren't getting the proper follow-up. A disturbing finding of the M. D. Anderson study was that only 59% of the patients who
had positive FOBTs received either colonoscopy
or the combination of flexible sigmoidoscopy
and a double-contrast barium enema, the followup procedures recommended by the American
Cancer Society. Significantly more gastroenterologists than other doctors provided the recommended follow-up. As might be expected, more
cancers were detected among those who received
the recommended follow-up than among the
other patients. (See the box on page 4 for recommendations on how primary care physicians can
use and follow up FOBTs.)
Advances in colon visualization have made
follow-up of positive FOBTs less disagreeable to
patients. In sigmoidoscopy, which can be performed by trained family physicians, a flexible
scope has replaced the rigid scope, which many
patients found uncomfortable. Sigmoidoscopy
costs about $150. Unlike sigmoidoscopy,
colonoscopy is performed under conscious seda tion by a gastroenterologist. It can take as little as
15-20 minutes if performed by an experienced

gastroenterologist. Colonoscopy costs about
$1000 and, as a follow-up to a positive FOBT, is
covered by some insurers. One advantage of
colonoscopy is that any polyps observed during
the procedure can be removed immediately.
Ronelle A. DuBrow, M.D., of the M. D. Anderson Department ofDiagnostic Radiology, is implementing a virtual colonoscopy system that will be
even less invasive than regular colonoscopy and
may not require pretreatment with laxatives, as
the current visualization systems do. Virtual
colonoscopy uses computerized tomography and
computer technology to make a two- or threedimensional image of the colon.
Genetic testing may complement the FOBT
Virtual colonoscopy is only one example of
how researchers and physicians at M. D. Anderson are trying to improve co1orecta1 cancer testing. "M. D. Anderson is conducting research on
new technologies and evaluating ways to use
existing technologies in the community," said
Levin. "We have a dual role and a dual responsibility."
Genetic testing for colorectal cancer is on the
horizon. About 6-10% of patients with colorectal
cancer have inherited an increased tendency to
develop it. Such patients can be identified by
their family histories, as they usually have one or
more first-degree relatives (mother, father, sisters, brothers, or children) who have had colorectal
cancer. If the genetic change that caused colorectal
cancer in their relatives can be identified, the rest
of the family can be tested for the change to
determine whether they too have inherited it and
thus an increased propensity to develop colorectal
cancer.
As with all genetic testing, the crux is determining what genetic change causes the disease.
However, counseling is also an integral part of
testing programs. Good genetic counseling must
include risk analysis for the patient and family,
education, and follow-up counseling on test results with all involved family members.
Many M. D. Anderson researchers are studying the genetics of colorectal cancer; they include
continued on page 4
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Christopher I. Amos, Ph.D., and Xifeng Wu,
M.D., Ph.D., of the Department of Epidemiology; Marsha L. Frazier, Ph.D., Patrick M. Lynch,
J.D., M.D., and Gideon Steinbach, M.D., Ph.D.,
of the Department of Gastrointestinal Oncology
and Digestive Diseases; Ellen R. Gritz, Ph.D.,
and Susan K. Peterson, M.P.H., of the Department of Behavioral Sciences; Sen Pathak, Ph.D.,
of the Department of Cell Biology; John M.
Skibber, M.D., of the Department of Surgical
Oncology; and Li Kuo Su, Ph.D., of the Department of Tumor Biology. There is also a collaborative M. D. Anderson-Johns Hopkins project in
which researchers are screening stool specimens
for malignant cells containing gene mutations.
In the meantime, FOBTs and flexible sigmoidoscopy have a central role in preventing death
from colorectal cancer. "Screening for colorectal

cancer reduces mortality," said Levin. "As inconvenient and, at the moment, as imprecise as the
FOBT is, it nevertheless saves lives . We want to
encourage the public and primary care physicians
to use FOBTs and flexible sigmoidoscopy. I began my career as a gastroenterologist, and I treated
a lot of patients with late-stage disease . Now I'd
like to help prevent some of that disease."
-MAUREEN E. GOODE
REFERRALS. Physicians who d esire additional information may write Dr. Levin or Ms. Johnson, Division
of Cancer Prevention, Box 203 , The University of
Texas M. D. Anderson Cancer Center, 1515 Holcombe
Blvd., Houston, Texas 77030, or call (713) 7920990. To refer a patient to M. D. Anderson, call the
New Patient Referral Office at (800 ) 392-1611 or
(713) 792-6161. ■

How primary care physicians can test for colorectal cancer
Primary care physicians have a vital role in identifying colorectal cancer at its earlier,
treatable stages. Here are some recommendations for colorectal cancer screen ing :

1. Ask your patients if they have relatives with colorectal . cancer. Because of their
increased risk of developing colorectal cancer, individuals with one or more first-degree
relatives who have colorectal cancer should be under the care of a gastroenterol ogist
and be monitored by colonoscopy, not FOBTs, at periodic intervals determined by their
gastroenterologists.
2. Prescribe colonoscopy, not FOBTs, for symptomatic patients. The sym ptoms of
colorectal cancer include rectal bleeding, change in bowel habits, abdomi nal pain,
nausea, vomiting, weakness due to anemia, rectal pain or pressure, and narrowing of
stool.
3. Make the FOBT part of your annual examination of asymptomatic patients age 50
or older without a family history of colorectal cancer. Use non hydrated guaiac-based
kits that test stool samples. "Nurses can have a very important role in reminding
physicians and patients about annual exams," said Constance Johnson.
4. Recommend flexible sigmoidoscopy every 5 years for asymptomatic patients age
50 or older. Levin commented that primary care physicians should be proficient in
performing this examination. He expressed the hope that Medicare would reimburse
physicians for this procedure in the future.

5. Encourage all patients who have positive FOBTs to have colonoscopy or flexible
sigmoidoscopy and barium enemas. Refer them to an experienced gastroenterologist.
6. Remind patients with polyps, adenomas, or colorectal cancer to have periodic
colonoscopy at the intervals recommended by their gastroenterologists.
-MAUREEN
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Cancer genetics program
continued from page 8

sider the merits of potential prophylactic interventions. When prevention is not possible, however, the next goal is to initiate early detection
and curative interventions."
The Human Clinical Cancer Genetics Program also is looking at genes involved in susceptibility to colon cancer. As new predisposing
genes are identified, the program will be extended to include other cancers as well. Individuals can be referred to the program by a physician,
or they can contact the institution themselves.
Program to screen for BRCAl and BRCA2
mutations
The program will initially focus on mutations
of the breast cancer 1 (BRCAl) and breast cancer 2 (BR CA2) genes. The involvement of
BRCAl in the development of breast and ovarian cancer was first recognized about five years
ago. Four years later, the gene was successfully
cloned, providing researchers with a better understanding of its activity. About 60% of individuals who have a mutation of BRCAl will get
ovarian cancer in their lifetime; about 80% will
get breast cancer. In addition, the risks for colon
and prostate cancer are three to four times higher
in individuals who carry the BRCAl mutation
than in the normal population. So a person who
carries a mutation in this gene should be counseled about screening options for all these types
of cancer.
Mutation of BRCA2 causes a higher incidence
of breast cancer than ovarian cancer as well, particularly among young adults. And although breast
cancer is rare in males, it does occur in some men
with an abnormal BRCA2 gene. "Any individual-man or woman-with a family history of
male breast cancer should be counseled for the
possible presence of a BRCA2 mutation," Mills
said.
Counseling complements genetic testing
The breast/ovarian cancer pilot project involves three visits to M. D. Anderson: for risk
assessment, pre-test counseling and genetic testing, and post-test counseling. It takes about six
weeks to complete the program.
Risk assessment. During the risk assessment
visit, Mills or Strong, along with Paula Rieger,
M.S.N., certified nurse practitioner, interviews

the individual to determine such factors as: 1)
overall family structure and occurrences of cancer
in relatives, 2) how close in relation the individual
is to any cancer patients, 3) the ages of the
patients at diagnosis, 4) the types of cancer diagnosed, and 5) the number of cases of different
types of cancer. With this information, a pedigree, or family medical chart, is developed and
used to assess the individual's potential risk of
carrying the mutation that causes breast or ovarian cancer. "Low risk" means there is a 1 %
chance or less that the individual carries the
mutation, and "high risk" means there is a 10% or
greater chance. "Moderate risk" means either
that the individual's risk falls somewhere between
low and high or that there is insufficient information to assess risk. For example, a 34-year-old
woman can be assumed to be at high risk for
breast cancer if her mother, two of her mother's
three sisters, and her grandmother were all diagnosed with the disease. However, if this same
woman could recall only one family member in
two generations who had cancer, a 58-year-old
distant cousin with colon cancer, she would be
determined to be at low risk.
An inherited abnormality in one or more genes
does not guarantee a diagnosis of cancer. "There
is not 100% penetrance; there are other factors
that determine whether or not cancer occurs,"
Mills said. "However, someone who inherits an
abnormality will essentially be at increased risk
for his or her whole life."
Individuals considered to be at high risk receive genetic counseling, which includes education about cancer and genetic testing, discussion
of risks and benefits of testing and implications of
test results, exploration of surveillance and surgical options, and assessment of need for psychological or psychiatric intervention. Individuals
determined to be at high or moderate risk would
be offered enrollment in a surveillance program
through the clinic, such as yearly mammograms.
Genetic testing. It is not uncommon for individuals to forgo genetic testing, Mills said. "This
area of research is still new, and it generates
mixed opinions." The concerns and emotions
that a participant may face are described in the
informed consent form for the program (see the
box on page 6). "Most of the time, all we can
deliver is bad news or no news, and many people
may simply not want to know that they may be at
high risk of cancer," Mills said. "Many may consider cancer a matter of chance that cannot be
altered anyway; others may be burdened by the
continued on page 7
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Informed consent explains concerns about genetic testing
I

Genetic screening is a complex issue, and helping people make informed decisions about
participating in this type of study can be challenging. Drs. Mills and Strong and their colleag ues
have carefully described the procedure, its benefits, and associated risks in the informed consent
document that each participant will read and sign. The section of the form that describes ri sks
is reproduced here. In constructing the form, and particularly this section, the study team has t ried
to be sensitive to the varying cultural, educational, and social factors that are likely to influence
potential participants' decisions.

Risks, Side Effects, and Discomforts to Participants: Many people are pleased with
genetic testing, whether the results are positive or negative, because it allows them to plan
their lives with regard to their cancer risk. However, for others, finding out that they have
a change in a gene that is linked to higher risk of cancer may make them feel angry or
shocked. They may deny that they have the abnormal gene. They may worry about thei r
own health and that of family members. They may worry about passing the gene on to thei r
children. They may feel that getting and keeping a job will be much harder. They may have
different feelings about themselves. They may worry about medical costs and insurance.
Finding out that gene changes linked to higher risk of cancer are not present may cause a
person to feel guilt or joy.

I

I

I

I

I

I

I

I

I

If the person does have the changed gene, he or she may decide to tell other family
members who may also have the changed gene. This may not be welcome news to others
in the family.
During counseling, other news about family issues may be revealed as a result of the testing
and of the person finding out the test results. These issues may have to do with adoption
or paternity (father's identity). Knowing such things may cause changes in a person's
relationships with other family members. Information of this type will not be revealed to
people in the study unless it will affect medical or childbearing decisions.

I

I

I

I

If people know they have the changed gene, they may have to make this known to an
insurance company when applying for a policy. An insurance company may refuse to cover
a person or may charge a higher price for insurance. Legislation to correct this potential
problem is pending.

I

I

If an employer learns of the test results, a person may be denied a job offer.
Although the changed gene increases the chance that cancer will develop, not all people
with the changed gene will get cancer. It is not known when cancer may occur in people
who have the changed gene.
Not all the changes in a gene that may increase the risk for cancer are known. A change in
a gene may be missed. There may be other genes linked to breast cancer and ovarian cancer
that haven't been found or studied yet.

I

I

I

I

Results of gene testing may be unclear. The person may complete the test without learning
more about his or her own risk of getting cancer.

I

Errors may occur in the laboratory.

I

If no changes in the gene are found, the person still has the same risk of getting breast
cancer or ovarian cancer that all people in general have.

I

I
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Cancer genetics program
continued from page 5

guilt that they may test negative but another
relative may test positive." Until appropriate laws
are passed, another major concern patients may
have is insurance discrimination. Furthermore,
the efficacy of current screening or prevention
procedures is as yet unclear.
Other participants are excited about the possibilities that testing offers and anxious to take
advantage of whatever prevention or screening
mechanisms are available, even investigational
ones. Some people agree to testing but opt not to
know the results; however, their participation still
benefits the research effort.
For the genetic test, a blood sample is drawn
from the individual and tested for the presence of
a mutated BRCAl or BRCA2 gene. "The best
tests have a 30% false- negative factor, which means
that about 30% of individuals who show no mutation in the test could still have an altered BRCAl
or BR CA2 gene and be at a high risk to develop
cancer," Mills ~aid. "However, this test can detect 70% of the abnormalities in BRCAl or
BRCA2 that contribute to breast and ov;irian
cancer. We think it is remarkable that within the
short period of time testing has been available, we
can accurately detect such a large percentage of
these genetic m utations."
Post-test counseling. The final step in the program is post-test counseling and assessment.
During this visit, the physicians discuss the test
results and make recommendations for followup. Some patients will be referred back to their
regular physicians, Mills explained, whereas others may be referred to M. D. Anderson's breast or
gynecologic clinic for further screening. "The
news may be 'Yes, you have the altered gene, and
we recommend further screening and assessment.'
Or it may be 'No, you don't have the altered
gene.' At other times, when the results are not
conclusive enough to determine risk or there is
potential for a false negative, we end up saying,
'You may not have the altered gene, but we must
still consider you to be at potentially increased
risk.' Our advice would then be that they enter a
surveillance program and follow prevention guidelines for the general population."
In both pre- and post-test counseling, the
potential impact on the psychological well-being
of the participant and his or her family members
is discussed. "Learning one's genetic risk of get-

ting cancer may be as emotionally and physically
stressful as accepting disease diagnosis," said Mills.
"We explain what the participants can expect as
far as lifestyle changes and advise them on coping
with those changes." Psychological or psychiatric
consultation is available for individuals who experience distress as a result of the genetic testing.
Mills explained that the Human Clinical Cancer Genetics Program adheres to the guidelines
of M. D. Anderson's institutional review board.
"We are aware of and sensitive to the negative
ramifications a positive screening for breast or
ovarian cancer could have on an individual's insurability, employability, and per_sonal life," he
said. "Any information generated through our
program will be maintained exclusively for the
private use of the participant and his or her physician."
Program will support cancer research efforts
Understanding the heritable genetic changes
that can lead to the onset of cancer is an important step in the development of new, more effective cancer prevention, diagnostic, and treatment
strategies, Mills said. "Data from some preliminary studies indicate that cancers resulting from
an inherited abnormality may behave differently
from cancers resulting from sporadic mutations.
The information we obtain through the breast/
ovarian cancer pilot project will help us determine, for example, whether these different types
of cancers require different treatments."
As important as the research effort, however,
are the implications for patient awareness, said
Mills. "People get really excited about genetic
testing because it is new and because, as a screening mechanism, it has the potential for revolutionizing our approach to cancer. But as important
are the steps that lead to and follow testing-risk
counseling, genetics counseling, and treatment
counseling. Key outcomes of this program will be
communicating the information individuals need
to make appropriate decisions and providing the
support they need to cope with the prospect of
cancer."
-VICKIE

J.
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REFERRALS. Physicians who have questions may call
Christie Cook, administrative manager, at (713) 745 8045 or Paula Rieger, certified nurse practitioner, at
(713) 745-8044 or write to them at Box 51, The
University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Blvd., Houston, TX 77030. To refer
a patient, call the New Patient Referral Office at (800)
392-1611 or (713) 792-6161. ■
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Genetic counseling and testing help patients evaluate cancer risk

New program focuses on
inherited predisposition to

breast and ovarian cancer
Cancer Genetics
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Gordon Mills is chairman
of the Department of
Molecular Oncology

One of the most important outcomes of cancer research in recent years has been a clearer
understanding of the role of genetics in the development of cancer. Studies have shown that
about 5-10% of all cancers can be attributed to
genetic changes that are inherited in some families. Within the past five years, scientists ha e
identified and cloned some of the genetic muta tions that have been shown to run in families. As
part of its ongoing cancer prevention program,
M. D. Anderson Cancer Center has established a
Human Clinical Cancer Genetics Program to study
heritable genetic mutations that predispose certain individuals to cancer. The initial focus will be
on the mutations that cause breast and ovarian
cancer.

Goals are prevention and early detection
The breast/o arian cane r pilot pr j t f th
Human Clinical Cancer G n tic Program i d signed to help individuals ho e famil hi tory
suggests a predispo ition to cane r aluat th
risk of disease de elopment and d t rmin \: h th r
surveillance or interventions ar appropriate.
Gordon Mills, M.D., chairman of the Department of Molecular Oncology and Louis Strong,
M.D., geneticist and professor of e perimental
pediatrics, are codirectors of the ne\: program
which was established under the Division of Cancer Pre ention. "The basis of our program i
cancer pre ention, Mills e plained. 'Our goal i
to help individuals assess their ri k for brea t and
o arian cancer so that the will be able to concontinued on page 5

